SK bioscience Receives Approval for Global Clinical Trials of mRNA Japanese Encephalitis Vaccine Candidate
- Written by PR Newswire Asia - News Pronto RSS
 |
- SK bioscience's first mRNA vaccine candidate is expected to enter clinical trials in Australia in February 2025, with interim results expected by 2026.
- Joint R&D project between SK and CEPI includes up to USD 40 million in initial funding support from CEPI.
- SK bioscience will respond to infectious diseases by expanding the development of...